表紙
市場調查報告書
商品編碼
1028783

全球核酸治療藥物市場 CDMO(合同製造組織)(2021-2030):按產品/技術/最終用戶

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Product, Technology, and End User - Analysis and Forecast, 2021-2030

出版日期: | 出版商: BIS Research Inc. | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計到 2030 年,核酸治療的合同研究組織 (CDMO) 市場將增長至 44.637 億美元。

人類基因組解碼和疾病分子相互作用中重要分子途徑的闡明為使用核酸的治療劑的開發提供了前所未有的機會和增長。為了繼續製造和開發這些治療劑,製藥公司與 CDMO(合同研究組織)合作,作為內部開發的強大替代方案。諸如將藥物開發外包給 CDMO 的動機增加以及對藥物的需求不斷增長等因素正在推動市場的增長。

本報告調查了全球核酸合同研究機構 (CDMO) 市場,並對市場進行了定義和概述,分析了市場影響因素、市場規模變化/預測以及化學合成/技術/終端。匯總了用戶、產品、地區/主要國家、競爭環境、主要公司簡介等各種類別。

目錄

第 1 章市場

  • 行業展望
  • 定義
  • 全球核酸治療 CDMO 市場的足跡
  • 核酸治療CDMOS現狀
  • 核酸在治療中的重要用途
  • 合成用於治療的核酸類型
    • 反義寡核甘酸 (ASO)/DNA 適體
    • RNA干擾(RNAi)/短干擾RNA(siRNA)
    • 微RNA
    • RNA適體/RNA誘餌
    • 核□
    • 環狀RNA
  • 市場動態
    • 增長動力
    • 生長抑製劑
    • 市場機會

第二章競爭形勢

  • 新服務/融資/投資
  • 法律法規
  • 併購
  • 聯盟/合作
  • 市場份額分析
  • 增長份額分析

第 3 章市場分析/預測:通過化學合成

  • 固相寡核甘酸合成
  • 液相寡核甘酸合成

第 4 章市場分析/預測:按技術

  • 柱基
  • 微陣列基礎

第 5 章市場分析/預測:按最終用戶

  • 製藥公司
  • 學術研究機構
  • 診斷實驗室

第 6 章市場分析/預測:按產品

  • 標準核酸
  • 微量核酸
  • 大規模核酸
  • 定制核酸
  • 修飾核酸
  • 入門
  • 探針
  • 其他核酸
  • 其他服務

第 7 章市場分析/預測:按地區/主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 其他領域

第 8 章競爭基準/公司簡介

  • 競爭基準
  • Agilent Technologies, Inc.
  • Ajinomoto Co. Inc.
  • Bachem Holding AG.
  • Biospring GmbH
  • Corden Pharma International
  • Danaher Corporation
  • Guangzhou Ruibo Biotechnology Co., Ltd.
  • KNC Laboratories Co., Ltd.
  • LGC Limited
  • Merck KGaA
  • Nippon Shokubai Co., Ltd.
  • Nitto Denko Avecia Inc.
  • QIAGEN N.V.
  • ST Pharm Co Ltd
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
  • Yamasa Corporation
目錄
Product Code: BHL1097SA

“Global Nucleic Acid Therapeutics CDMO Market to Reach $4,463.7 Million by 2030.”

Market Report Coverage - Nucleic Acid Therapeutics CDMO

Market Segmentation

  • Product - Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, Other Services
  • Chemical Synthesis - Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis
  • Technology - Column-Based Method, Microarray-Based Method
  • End User - Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, Rest-of-Europe
  • Asia-Pacific - Japan, China, India, Australia, Rest-of-Asia-Pacific
  • Rest-of-the-World

Market Growth Drivers

  • Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products
  • Reduction in Overall Manufacturing Cost at CDMOs
  • Rising Approvals of Nucleic Acid Therapeutics

Market Challenges

  • Lack of Expertise in Nucleic Acid Manufacturing
  • Supply Chain and Logistical Challenges
  • Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids

Market Opportunities

  • Increasing Outsourcing Trend Among Pharmaceutical Companies
  • Accelerating Research and Development Along with Technology
  • Growth in Developing Countries

Key Companies Profiled:

Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG, Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc., QIAGEN N.V., ST Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation.

Key Questions Answered in this Report:

  • What are the different types of nucleic acid therapies available in the global nucleic acid therapeutics CDMO market?
  • What are the key development strategies implemented by the key players to stand out in this global nucleic acid therapeutics CDMO market?
  • What are the manufacturing locations of the key companies within the global nucleic acid therapeutics CDMO market?
  • What are the various manufacturing technologies within the global nucleic acid therapeutics CDMO market?
  • How have the strategic collaborations among the key players provided a push to product development within the global nucleic acid therapeutics CDMO market?
  • Which are the leading companies that are dominating the global nucleic acid therapeutics CDMO market?
  • Based on the product type, which therapy in the global nucleic acid therapeutics CDMO market is anticipated to witness a massive rise in demand during the forecast period?
  • How is each segment of the global nucleic acid therapeutics CDMO market expected to grow during the forecast period, and what revenue is expected to be generated by each of these segments by the end of 2030?

Market Overview

The completion of human genome sequencing and the elucidation of the molecular pathways that are critical in the disease molecule interaction have offered an unprecedented opportunity and growth for the development of nucleic acid-based therapeutics. However, to keep with the manufacturing and development of such therapies, the pharmaceutical companies have established partnerships with the contract development and manufacturing company (CDMO) which are the viable alternatives to the in-house development of the drugs. Moreover, the success of the respective business model has also led these CDMOs to become an integral part of such pharmaceutical companies' value chain.

The increasing willingness to outsource drug development to the CDMOs, and the rising need for pharmaceuticals have resulted in the expansion of the global market for nucleic acid therapeutics CDMO.

In the past decade, there has been a vast increase in the amount of gene sequence information that has the potential to revolutionize the way diseases are categorized and treated. Traditional diagnoses, largely anatomical or descriptive in nature, are likely to be superseded by the molecular characterization of the disease. The fact that certain genes drive key disease processes will also enable the rational design of gene-specific therapeutics. Antisense oligonucleotides represent a technology that can play multiple roles in this process. Further, at present, there are 16 nucleic acid therapies approved by the FDA and EMA and many more in the pipeline implying the reliance and acceptance over the usage of such therapies in the market.

Within the research report, the market is segmented on the basis of product type, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of nucleic acid therapeutics CDMO market on the global level has created a buzz among companies to invest in the manufacturing of nucleic acid-based therapies. In the past five years (July 2017-July 2021), the nucleic acid therapeutics CDMO market witnessed approximately 31 notable key developments. These included one product launch, two regulatory and legal activities, three mergers and acquisitions, 24 synergistic developments (partnerships, collaborations, agreements, and business expansion activities).

On the basis of region, North America holds the largest share within the nucleic acid therapeutics CDMO manufacturing due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period of 2021-2030.

Table of Contents

1 Markets

  • 1.1 Industry Outlook
    • 1.1.1 Global Nucleic Acid Therapeutics CDMO Market Overview
  • 1.2 Product Definition
  • 1.3 Global Nucleic Acid Therapeutics CDMO Market Footprint, ($ Million), 2020-2030
  • 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
  • 1.5 Significant Usage of Nucleic Acid in Therapeutics
  • 1.6 Types of Nucleic Acid Synthesized for Therapeutics
    • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
    • 1.6.2 RNA interference [RNAi] and short interfering RNAs [siRNAs]
    • 1.6.3 MicroRNAs
    • 1.6.4 RNA Aptamers and RNA Decoys
    • 1.6.5 Ribozymes
    • 1.6.6 Circular RNAs
  • 1.7 Market Dynamics
    • 1.7.1 Market Drivers
      • 1.7.1.1 Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products
      • 1.7.1.2 Reduction in Overall Manufacturing Cost at CDMOs
      • 1.7.1.3 Rising Approvals of Nucleic Acid Therapeutics
    • 1.7.2 Restraints
      • 1.7.2.1 Lack of Expertise in Nucleic Acid Manufacturing
      • 1.7.2.2 Supply Chain and Logistical Challenges
      • 1.7.2.3 Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids
    • 1.7.3 Opportunities
      • 1.7.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies
      • 1.7.3.2 Accelerating Research and Development Along with Technology
      • 1.7.3.3 Growth in Developing Countries

2 Competitive Landscape

  • 2.1 New Offerings and Funding and Investments
  • 2.2 Regulatory and Legal
  • 2.3 Mergers and Acquisitions
  • 2.4 Synergistic Activities
  • 2.5 Market Share Analysis
  • 2.6 Growth Share Analysis

3 Chemical Synthesis Method

  • 3.1 Overview
    • 3.1.1 Solid-Phase Oligonucleotide Synthesis
      • 3.1.1.1 Advantages and Challenges of SPOS
      • 3.1.1.2 Method
        • 3.1.1.2.1 Deprotecting/Detritylation
        • 3.1.1.2.2 Coupling
        • 3.1.1.2.3 Oxidation/Sulfurization
        • 3.1.1.2.4 Capping
      • 3.1.1.3 Cleavage and Deprotection
      • 3.1.1.4 Purification
    • 3.1.2 Liquid-Phase Oligonucleotide Synthesis
      • 3.1.2.1 Advantages and Challenges of LPOS

4 Technology

  • 4.1 Overview
    • 4.1.1 Column-Based Method
    • 4.1.2 Microarray-Based Method

5 End-User

  • 5.1 Overview
    • 5.1.1 Pharmaceutical Companies
    • 5.1.2 Academic Research Institute
    • 5.1.3 Diagnostic Laboratories

6 Products

  • 6.1 Global Nucleic Acid Therapeutics CDMO Market (by Product)
    • 6.1.1 Standard Nucleic Acid
    • 6.1.2 Micro-Scale Nucleic Acid
    • 6.1.3 Large-Scale Nucleic Acid
    • 6.1.4 Custom Nucleic Acid
    • 6.1.5 Modified Nucleic Acid
    • 6.1.6 Primers
    • 6.1.7 Probes
    • 6.1.8 Other Nucleic Acid
    • 6.1.9 Other Services

7 Regions

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest-of-Europe
  • 7.4 Asia-Pacific
    • 7.4.1 China
    • 7.4.2 India
    • 7.4.3 Japan
    • 7.4.4 Australia
    • 7.4.5 Rest-of-Asia-Pacific
  • 7.5 Rest-of-the-World

8 Markets - Competitive Benchmarking & Company Profiles

  • 8.1 Competitive Benchmarking
  • 8.2 Agilent Technologies, Inc.
    • 8.2.1 Company Overview
    • 8.2.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.2.3 Financials
    • 8.2.4 Key Insights About Financial Health of the Company
    • 8.2.5 SWOT Analysis
  • 8.3 Ajinomoto Co. Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Role of Ajinomoto Co. Inc. in Global Nucleic Acid Therapeutics CDMO Market
    • 8.3.3 Financials
    • 8.3.4 SWOT Analysis
  • 8.4 Bachem Holding AG.
    • 8.4.1 Company Overview
    • 8.4.2 Role of Bachem Holding AG. in Global Nucleic Acid Therapeutics CDMO Market
    • 8.4.3 SWOT Analysis
  • 8.5 Biospring GmbH
    • 8.5.1 Company Overview
    • 8.5.2 Role of Biospring GmbH in Global Nucleic Acid Therapeutics CDMO Market
    • 8.5.3 SWOT Analysis
  • 8.6 Corden Pharma International
    • 8.6.1 Company Overview
    • 8.6.2 Role of Corden Pharma International in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.6.3 SWOT Analysis
  • 8.7 Danaher Corporation
    • 8.7.1 Company Overview
    • 8.7.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.7.3 Financials
    • 8.7.4 Key Insights About Financial Health of the Company
    • 8.7.5 SWOT Analysis
  • 8.8 Guangzhou Ruibo Biotechnology Co., Ltd.
    • 8.8.1 Company Overview
    • 8.8.2 Role of Guangzhou Ruibo Biotechnology Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.8.3 SWOT Analysis
  • 8.9 KNC Laboratories Co., Ltd.
    • 8.9.1 Company Overview
    • 8.9.2 Role of KNC Laboratories Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.9.3 Financials
    • 8.9.4 SWOT Analysis
  • 8.1 LGC Limited
    • 8.10.1 Company Overview
    • 8.10.2 Role of LGC Limited in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.10.3 Financials
    • 8.10.4 Key Insights About Financial Health of the Company
    • 8.10.5 SWOT Analysis
  • 8.11 Merck KGaA
    • 8.11.1 Company Overview
    • 8.11.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.11.3 Financials
    • 8.11.4 Key Insights About Financial Health of the Company
    • 8.11.5 SWOT Analysis
  • 8.12 Nippon Shokubai Co., Ltd.
    • 8.12.1 Company Overview
    • 8.12.2 Role of Nippon Shokubai Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.12.3 Financials
    • 8.12.4 Key Insights About Financial Health of the Company
    • 8.12.5 SWOT Analysis
  • 8.13 Nitto Denko Avecia Inc.
    • 8.13.1 Company Overview
    • 8.13.2 Role of Nitto Denko Avecia Inc. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.13.3 SWOT Analysis
  • 8.14 QIAGEN N.V.
    • 8.14.1 Company Overview
    • 8.14.2 Role of QIAGEN N.V. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.14.3 Financials
    • 8.14.4 Key Insights About Financial Health of the Company
    • 8.14.5 SWOT Analysis
  • 8.15 ST Pharm Co Ltd
    • 8.15.1 Company Overview
    • 8.15.2 Role of ST Pharm Co Ltd in Global Nucleic Acid Therapeutics CDMO Market
  • 8.16 Sumitomo Chemical Co., Ltd.
    • 8.16.1 Company Overview
    • 8.16.2 Role of Sumitomo Chemical Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.16.3 Financials
    • 8.16.4 Key Insights About Financial Health of the Company
    • 8.16.5 SWOT Analysis
  • 8.17 Syngene International Limited
    • 8.17.1 Company Overview
    • 8.17.2 Role of Syngene International Limited in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.17.3 Financials
    • 8.17.4 Key Insights About Financial Health of the Company
    • 8.17.5 SWOT Analysis
  • 8.18 Thermo Fisher Scientific Inc.
    • 8.18.1 Company Overview
    • 8.18.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.18.3 Financials
    • 8.18.4 Key Insights About Financial Health of the Company
    • 8.18.5 SWOT Analysis
  • 8.19 Wuxi AppTec
    • 8.19.1 Company Overview
    • 8.19.2 Role of Wuxi AppTec in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.19.3 Financials
    • 8.19.4 Key Insights About Financial Health of the Company
    • 8.19.5 SWOT Analysis
  • 8.2 Yamasa Corporation
    • 8.20.1 Company Overview
    • 8.20.2 Role of Yamasa Corporation in the Global Nucleic Acid Therapeutics CDMO Market
    • 8.20.3 SWOT Analysis

List of Figures

  • Figure 1: Global Nucleic Acid Therapeutics CDMO Market, Realistic and Optimistic Scenario, $Million
  • Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics
  • Figure 3: Share of Key Market Strategies and Developments, July 2017-July 2021
  • Figure 4: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company), 2019-2020
  • Figure 5: Global Nucleic Acid Therapeutics CDMO Market Research Methodology
  • Figure 6: Primary Research Methodology
  • Figure 7: Global Nucleic Acid Therapeutics CDMO Market, $Million, 2020-2030
  • Figure 8: Optimistic View of Global Nucleic Acid Therapeutics CDMO Market, $Million
  • Figure 9: Overview of CRO and CDMO Services
  • Figure 10: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics
  • Figure 11: Deal Value of Mergers and Acquisitions Involving Cell and Gene Therapies (2016-2019)
  • Figure 12: Share of Key Market Strategies and Developments, July 2017-July 2021
  • Figure 13: Share of Mergers and Acquisitions (by Company), 2017-2021
  • Figure 14: Share of Synergistic Activities (by Company), 2017-2021
  • Figure 15: Market Share Analysis for Global Nucleic Acid Therapeutics CDMO Market, 2020
  • Figure 16: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company),2019- 2020
  • Figure 17: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
  • Figure 18: Share of Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), 2020 and 2030
  • Figure 19: Solid-Phase Oligonucleotide Synthesis Market Size and Forecast
  • Figure 20: Liquid-Phase Oligonucleotide Synthesis Market Size and Forecast
  • Figure 21: Share of Global Nucleic Acid Therapeutics CDMO Market (by Technology), 2020 and 2030
  • Figure 22: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), 2020-2030
  • Figure 23: Global Nucleic Acid Therapeutics CDMO Market (by Microarray-Based Method), 2020-2030
  • Figure 24: Global Nucleic Acid Therapeutics CDMO Market, by End User, 2020 and 2030 ($Million)
  • Figure 25: Global Nucleic Acid Therapeutics CDMO Market, by Pharmaceutical and Biotechnology Companies
  • Figure 26: Global Nucleic Acid Therapeutics CDMO Market, by Academic Research Institutes
  • Figure 27: Global Nucleic Acid Therapeutics CDMO Market, by Diagnostic Laboratories
  • Figure 28: Global Nucleic Acid Therapeutics CDMO Market (by Product)
  • Figure 29: Share of Global Nucleic Acid Therapeutics CDMO Market (by Product), 2020 and 2030 ($Million)
  • Figure 30: Global Nucleic Acid Therapeutics CDMO Market, by Standard Nucleic Acid
  • Figure 31: Global Nucleic Acid Therapeutics CDMO Market, by Micro-Scale Nucleic Acid
  • Figure 32: Global Nucleic Acid Therapeutics CDMO Market, by Large-Scale Nucleic Acid Market
  • Figure 33: Global Nucleic Acid Therapeutics CDMO Market, by Custom Nucleic Acid
  • Figure 34: Global Nucleic Acid Therapeutics CDMO Market, by Modified Nucleic Acid
  • Figure 35: Global Nucleic Acid Therapeutics CDMO Market Primer Market, by Primers
  • Figure 36: Global Nucleic Acid Therapeutics CDMO Market, by Primer
  • Figure 37: Global Nucleic Acid Therapeutics CDMO Market, by Others NA
  • Figure 38: Global Nucleic Acid Therapeutics CDMO Market, Other Services
  • Figure 39: Global Nucleic Acid Therapeutics CDMO Market (by Region), Million Units, 2020-2030
  • Figure 40: Share of North America Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million
  • Figure 41: North America: Market Dynamics
  • Figure 42: U.S. Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million
  • Figure 43: Canada Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million
  • Figure 44: Share of Europe Nucleic Acid Therapeutics CDMO Market (by Country), 2020-2030, $Million
  • Figure 45: Europe: Market Dynamics
  • Figure 46: Germany Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 47: U.K. Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 48: France Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 49: Italy Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 50: Spain Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 51: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 52: APAC: Market Dynamics
  • Figure 53: Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million
  • Figure 54: China Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 55: India Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 56: Japan Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 57: Australia Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 58: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 59: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
  • Figure 60: Shares of Key Company Profiles
  • Figure 61: Agilent Technologies, Inc.: Product Portfolio
  • Figure 62: Agilent Technologies, Inc.: Overall Financials, 2018-2020
  • Figure 63: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
  • Figure 64: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
  • Figure 65: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
  • Figure 66: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 67: Ajinomoto Co. Inc,: Overall Product Portfolio
  • Figure 68: Ajinomoto Co., Inc.: Overall Financials, 2017-2019
  • Figure 69: Ajinomoto Co., Inc.: Revenue (by Segment), 2017-2019
  • Figure 70: Ajinomoto Co., Inc.: SWOT Analysis
  • Figure 71: Bachem Holding AG.: Overall Product Portfolio
  • Figure 72: Bachem Holding AG.: SWOT Analysis
  • Figure 73: Biospring GmbH: Overall Product Portfolio
  • Figure 74: Biospring GmbH: SWOT Analysis
  • Figure 75: Corden Pharma International: Overall Product Portfolio
  • Figure 76: Corden Pharma International: SWOT Analysis
  • Figure 77: Danaher Corporation: Product Portfolio
  • Figure 78: Danaher Corporation: Overall Financials, 2018-2020
  • Figure 79: Danaher Corporation: Revenue (by Segment), 2018-2020
  • Figure 80: Danaher Corporation: Revenue (by Region), 2018-2020
  • Figure 81: Danaher Corporation: R&D Expenditure, 2018-2020
  • Figure 82: Danaher Corporation: SWOT Analysis
  • Figure 83: Guangzhou Ruibo Biotechnology Co., Ltd.: Product Portfolio
  • Figure 84: Guangzhou Ruibo Biotechnology Co., Ltd: SWOT Analysis
  • Figure 85: KNC Laboratories Co., Ltd.: Overall Product Portfolio
  • Figure 86: KNC Laboratories Co., Ltd.: Overall Financials, 2018-2020
  • Figure 87: KNC Laboratories Co., Ltd.: SWOT Analysis
  • Figure 88: LGC Limited: Overall Product Portfolio
  • Figure 89: LGC Limited: Overall Financials, 2018-2020
  • Figure 90: LGC Limited: Revenue (by Segment), 2018-2020
  • Figure 91: LGC Limited: R&D Expenditure, 2018-2020
  • Figure 92: LGC Limited: SWOT Analysis
  • Figure 93: Merck KGaA: Product Portfolio
  • Figure 94: Merck KGaA: Overall Financials, 2018-2020
  • Figure 95: Merck KGaA: Revenue (by Segment), 2018-2020
  • Figure 96: Merck KGaA: Revenue (by Region), 2018-2020
  • Figure 97: Merck KGaA: R&D Expenditure, 2018-2020
  • Figure 98: Merck KGaA: SWOT Analysis
  • Figure 99: Nippon Shokubai Co., Ltd.: Overall Financials, 2018-2020
  • Figure 100: Nippon Shokubai Co., Ltd: Revenue (by Segment), 2018-2020
  • Figure 101: Nippon Shokubai Co., Ltd: R&D Expenditure, 2018-2020
  • Figure 102: Nippon Shokubai Co., Ltd: SWOT Analysis
  • Figure 103: Nitto Denko Avecia Inc.: Product Portfolio
  • Figure 104: Nitto Denko Avecia Inc.: SWOT Analysis
  • Figure 105: QIAGEN N.V.: Product Portfolio
  • Figure 106: QIAGEN N.V.: Overall Financials, 2018-2020
  • Figure 107: QIAGEN N.V.: Revenue (by Segment), 2018-2020
  • Figure 108: QIAGEN N.V.: Revenue (by Region), 2018-2020
  • Figure 109: QIAGEN N.V.: R&D Expenditure, 2018-2020
  • Figure 110: QIAGEN N.V.: SWOT Analysis
  • Figure 111: ST Pharm Co Ltd : Overall Product Portfolio
  • Figure 112: ST Pharm Co Ltd: SWOT Analysis
  • Figure 113: Sumitomo Chemical Co., Ltd.: Overall Product Portfolio
  • Figure 114: Sumitomo Chemical Co., Ltd: Overall Financials, 2018-2020
  • Figure 115: Sumitomo Chemical Co., Ltd.: Revenue (by Segment), 2018-2020
  • Figure 116: Sumitomo Chemical Co., Ltd: R&D Expenditure, 2018-2020
  • Figure 117: Sumitomo Chemical Co., Ltd.: SWOT Analysis
  • Figure 118: Syngene International Limited: Overall Product Portfolio
  • Figure 119: Syngene International Limited: Overall Financials, 2018-2020
  • Figure 120: Syngene International Limited: Revenue (by Region), 2018-2020
  • Figure 121: Syngene International Limited: R&D Expenditure, 2018-2020
  • Figure 122: Syngene International Limited: SWOT Analysis
  • Figure 123: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 124: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
  • Figure 125: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
  • Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
  • Figure 127: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 128: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 129: Wuxi AppTec: Overall Product Portfolio
  • Figure 130: Wuxi AppTec: Overall Financials, 2018-2020
  • Figure 131: Wuxi AppTec: Revenue (by Segment), 2018-2020
  • Figure 132: Wuxi AppTec: Revenue (by Region), 2018-2020
  • Figure 133: Wuxi AppTec: R&D Expenditure, 2018-2020
  • Figure 134: Wuxi AppTec: SWOT Analysis
  • Figure 135: Yamasa Corporation: Overall Product Portfolio
  • Figure 136: Yamasa Corporation: SWOT Analysis

List of Tables

  • Table 1: Oligonucleotide Therapies Approved by the FDA
  • Table 2: Nucleic Acid Therapies Approved by FDA and EMA
  • Table 3: Companies offering Standard Nucleic Acid
  • Table 4: Companies offering Micro-Scale Nucleic Acid
  • Table 5: Companies offering Large-Scale Nucleic Acid
  • Table 6: Companies offering Custom Nucleic Acid
  • Table 7: Companies offering Modified Nucleic Acid
  • Table 8: Companies offering Primers
  • Table 9: Companies offering Probes
  • Table 10: Companies offering Other NA
  • Table 11: Companies offering Other Services